毒蕈碱型乙酰胆碱受体激动剂作为精神分裂症新型治疗
精神分裂症现有抗精神病药对核心症状谱疗效有限且副作用负担重,亟需新型耐受性好的药物。约25年前毒蕈碱型乙酰胆碱受体激动剂占诺美林在阿尔茨海默病患者中报告可减轻精神病性症状并改善认知,随后在一项急性精神病性慢性精神分裂症患者的小型研究中得到确认。本文讨论mAChR生物学与药理学进展、各受体亚型及下游效应器和关键神经回路的作用,并更新在研新型mAChR激动剂状态。
要点
- 现有抗精神病药对精神分裂症核心症状谱疗效有限且副作用负担重、耐受性差。
- 占诺美林约25年前在阿尔茨海默病患者中报告减轻精神病性症状并改善认知。
- 占诺美林抗精神病与促认知特性在急性精神病性慢性精神分裂症患者小型研究中得到确认。
核心结论
- mAChR激动剂是潜在治疗精神分裂症及其他精神病性障碍的新机制方向。
- 需新型、机制独特且耐受性更好的药物,尤其针对阳性、阴性及认知症状。
研究设计与样本
- 本文为综述,讨论mAChR生物学与药理学进展及在研新型mAChR激动剂现状。
主要发现
- 占诺美林约25年前在阿尔茨海默病患者中报告减轻精神病性症状并改善认知。
- 占诺美林抗精神病与促认知特性在急性精神病性慢性精神分裂症患者小型研究中得到确认。
- 这些意外临床发现推动学术界与工业界将mAChR作为治疗精神分裂症的新靶点。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. An unmet need remains for novel, mechanistically unique, and better tolerated therapeutic agents for treating schizophrenia, especially those that treat not only positive symptoms but also the negative and cognitive symptoms of the disease. Almost 25 years ago, the muscarinic acetylcholine receptor (mAChR) agonist xanomeline was reported to reduce psychotic symptoms and improve cognition in patients with Alzheimer's disease. The antipsychotic and procognitive properties of xanomeline were subsequently confirmed in a small study of acutely psychotic patients with chronic schizophrenia. These unexpected clinical findings have prompted considerable efforts across academia and industry to target mAChRs as a new approach to potentially treat schizophrenia and other psychotic disorders. The authors discuss recent advances in mAChR biology and pharmacology and the current understanding of the relative roles of the various mAChR subtypes, their downstream cellular effectors, and key neural circuits mediating the reduction in the core symptoms of schizophrenia in patients treated with xanomeline. They also provide an update on the status of novel mAChR agonists currently in development for potential treatment of schizophrenia and other neuropsychiatric disorders.
引用
- Paul SM, Yohn SE, Popiolek M, et al. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Am J Psychiatry. 2022. PMID: 35758639. doi:10.1176/appi.ajp.21101083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。